ALLMedicine™ Adult Brain Tumor Center

Feb 4th, 2023 - Glioblastoma multiforme (GBM) is an aggressive form of adult brain tumor that can arise from a low-grade astrocytoma. In recent decades, several new conventional therapies have been developed that have significantly improved the prognosis of patie...

Feb 3rd, 2023 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Dec 10th, 2022 - Evidence regarding the relationship between preoperative platelet and 30-day postoperative mortality of intracranial tumor patients undergoing craniotomy is still limited. Therefore, the present research was conducted to explore the link of the pl...

Nov 30th, 2022 - Glioblastoma is the most aggressive type of primary adult brain tumor. The median survival of patients with glioblastoma remains approximately 15 months, and the 5-year survival rate is less than 10%. Current treatment options are limited, and the...

Jul 28th, 2022 - Glioblastoma (GBM) is the most common type of primary adult brain tumor. Glioma stem cell (GSC) residence and temozolomide (TMZ) resistance in GBM both contribute to poor patient outcome. TRAF4 is a scaffold protein with E3 ubiquitin ligase activi...

Feb 3rd, 2023 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Feb 7th, 2022 - Malignant brain tumors now represent the most frequent cause of cancer death in children. Despite aggressive and highly toxic multi-modality therapy including surgery, craniospinal radiation, and high-dose chemotherapy coupled with peripheral bloo...

Sep 13th, 2017 - Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will b...

Jan 14th, 2016 - A significant proportion of brain tumor patients treated with radiation or chemotherapy who are in disease remission experience cognitive sequelae from their treatment. Cognitive dysfunction can be of sufficient severity to interfere with their ab...

Aug 27th, 2015 - PRIMARY OBJECTIVES: I. To estimate the objective response rate (partial response [PR] or complete response [CR] ≥ 8 weeks) to sunitinib in 2 strata (recurrent/progressive/refractory high-grade glioma vs ependymoma) of recurrent or progressive brai...

Oct 6th, 2021 - Jian Li Campian, MD, PhD Medical Oncologist Assistant Professor of Medicine Siteman Cancer Center Washington University School of Medicine St. Louis, MO The concept that the immune system plays a pivotal role in the prevention and co...

Dec 20th, 2020 - Donald A. Berry, PhD An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme (GBM), putting into motion a biomarker-driven app...

Dec 5th, 2020 - Eric Kratky In January 2007, Erik Kratky was 21 and pursuing his undergraduate degree when he experienced bilateral leg weakness. Magnetic resonance imaging (MRI) revealed multiple spinal cord lesions in the T10 region and, after surgical resecti...

Apr 20th, 2015 - Adult brain tumor survivors taking donepezil, a drug approved for the treatment of Alzheimer’s disease, showed significant improvements in the cognitive functions of memory, motor speed, and dexterity, compared with those taking a placebo. However.

Sep 5th, 2008 - September 5, 2008 — A trio of genomic studies published yesterday in Nature and Science point to specific genes and signaling pathways that characterize 2 human cancers. The results suggest a potential for targeted therapies in glioblastoma multif...